Table 3.

Results from multivariate model predicting LVMI with DBP

Covariatea	Estimated Change (95% Confidence Interval)	P Value
DBP z score × V2b,c	−0.1% (−3.1% to 3.1%)	0.97
DBP z score × V4	4.9% (1.0% to 8.9%)	0.01
DBP z score × V6	−1.1% (−6.7% to 4.8%)	0.70
V4 versus V2	−36.1% (−49.3% to −19.5%)	<0.001
V6 versus V2	−33.1% (−55.2% to −0.1%)	0.05
Average height (cm) × V2d,e	−0.5% (−0.8% to −0.3%)	<0.001
Average height (cm) × V4	−0.2% (−0.5% to 0.0%)	0.10
Average height (cm) × V6	−0.3% (−0.6% to 0.1%)	0.14
GFR	0.0% (−0.1% to 0.1%)	0.54
Female sex	−2.9% (−7.5% to 1.8%)	0.22
African-American race	6.4% (0.6% to 12.7%)	0.03
Anemia	6.7% (2.2% to 11.4%)	0.003
ACEI or ARB	−0.9% (−5.3% to 3.6%)	0.68
Other antihypertensive medication	10.7% (3.1% to 18.9%)	0.005

^aVisit is a categorical variable. Additional covariates in the model (nonsignificant) are age, CKD diagnosis, duration of CKD, and duration of CKD–visit interaction.

^bOverall test for DBP–visit interaction (P=0.07).

^cSlope of V2 DBP z score versus average of V4 and V6 DBP z score slopes (P=0.41).

^dOverall test for height–visit interaction (P=0.001).

^eSlope of V2 height versus average of V4 and V6 heights (P=0.002).